MedPal AI PLCLSE: MPAL

MedPal AI: Exercise of Warrants

· Issued by MedPal AI PLC via RNS

Summary by 6ix AI

MedPal AI plc, an AI-powered digital health and pharmacy company, has received notice to exercise warrants (rights to buy new shares at a fixed price) over 1,570,000 new ordinary shares at 2.5 pence each, which would raise £39,250 for the company.

Key details

  • The new shares have a nominal value of 0.0002 pence each and will rank equally in all respects with the company's ordinary shares currently traded on AIM, the market where its shares trade.
  • Following admission of the new shares, MedPal AI's issued share capital will comprise 891,519,135 ordinary shares. This is the total number of voting rights, which shareholders may use to work out whether they must disclose their holdings under the Financial Conduct Authority's Disclosure and Transparency Rules.

What’s still pending

  • An application will be made for the 1,570,000 new shares to be admitted to trading on AIM, which is expected to occur on or around November 9, 2026.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/exercise-of-warrants-205

Medpal AI PLC
04 November 2026
 

4 November 2026

MedPal AI plc

("MedPal" or the "Company")

Warrant Exercise

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-powered, integrated digital health and pharmacy company, announces that the Company has received a notice to exercise warrants over a total of 1,570,000 new ordinary shares of 0.0002 pence each in the Company at an exercise price of 2.5 pence per share ("Warrant Shares"), raising £39,250 for the Company.

ADMISSION AND TOTAL VOTING RIGHTS

Application will be made for the 1,570,000 Warrant Shares to be admitted to trading on AIM which is expected to occur on or around 9 November 2026 ("Admission"). The Warrant Shares will rank pari passu in all respects with the ordinary shares of the Company currently traded on AIM.

Following Admission, the Company's issued share capital will comprise 891,519,135 ordinary shares of 0.0002p each. This number will represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please contact:

Enquiries:

MedPal AI plc

Jason Drummond, Chief Executive Officer

Via Square1 Consulting

Cairn Financial Advisers LLP (Nomad)

Louise O'Driscoll / Jo Turner

+44 (0) 20 7213 0880

Clear Capital Markets Limited

Bob Roberts

+44 (0) 20 3869 6080
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

MedPal AI PLC on 6ix

Earlier from MedPal AI

All MedPal AI news releases